Mucositis: The impact, biology and therapeutic opportunities of oral mucositis

Oral Oncology

Volumn 45, Issue 12, 2009, Pages 1015-1020

  Sonis, Stephen T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Mucositis; Radiation; Review; Toxicity

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ATL 104; CYTOTOXIC AGENT; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; METHOTREXATE; MITOGENIC AGENT; PALIFERMIN; PILOCARPINE; PLANT MEDICINAL PRODUCT; SCV 07; TRAU MEEL S; UNCLASSIFIED DRUG; ZINC;

ADDISON DISEASE; BIOLOGY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DERMATITIS; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HYPOPHARYNX CANCER; INJURY; LEUKEMIA; LIPID PEROXIDATION; LOW DRUG DOSE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; STOMATITIS; TONGUE CANCER;

ANIMALS; CRICETINAE; DRUG THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOUTH MUCOSA; RADIOTHERAPY; RISK FACTORS; STOMATITIS;

EID: 70449525211     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.08.006     Document Type: Review

References (46)

1. Sonis S.T. Is mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nat Clin Pract Oncol 2 (2005) 134-135
2. Spielberger R., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. New Engl J Med 351 (2004) 2590-2598
3. Keefe D.M. Mucositis guidelines: what have they achieved, and where to from here?. Support Care Cancer 14 (2006) 489-491
4. Elting L.S., Keefe D.M., Sonis S.T., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113 (2008) 2704-2713
5. Nonzee N.J., Dandade N.A., Patel U., et al. Evaluating the supportive costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Cost of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer center. Cancer 113 (2008) 1446-1452
6. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 (2001) 2201-2205
7. Grunberg S., Hesketh P., Randolph-Jackson P., et al. Risk, quality of life impact of mucosal injury among colorectal cancer patients receiving FOLFOX chemotherapy. Support Care Cancer 15 (2007) 704
8. Keefe D.M., Sonis S.T., and Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 13 (2008) 511-522
9. Gerullis H., Bergmann L., Mante L., et al. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 63 (2009) 1097-1102
10. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
11. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 (1998) 39-43
12. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 (2004) 277-284
13. Logan R.M., Stringer A.M., Bowen J.M., et al. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered. Cancer Chemother Pharmacol 63 (2009) 239-251
14. Sonis S.T. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5 (2007) 3-11
15. Sonis S.T., Haddad R., Posner M., et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43 (2007) 289-300
16. Logan R.M., Stringer A.M., Bowen J.M., et al. Serum levels of NF-κB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7 (2008) 1139-1145
17. Logan R.M., Gibson R.J., Sonis S.T., et al. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43 (2007) 395-401
18. Sonis S.T. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13 (2002) 380-389
19. Hwang D., Popat R., Bragdon C., et al. Effects of ceramide inhibition on experimental radiation-induced mucositis. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod 100 (2005) 321-329
20. Al-Dasooqi N., Gibson R.J., Bowen J.M., et al. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis. Cancer Chemother Pharmacol 64 (2009) 1-9
21. Uzel NG, Socransky S, Hwang D. The potential of periodontal pathogens in the development of experimental radiation-induced mucositis. Personal communication.
22. Tran K.T., Griffith L., and Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Rep Reg 12 (2004) 262-268
23. Basson M.D. In vitro evidence for matrix regulation of intestinal epithelial biology during mucosal healing. Life Sci 69 (2001) 3005-3018
24. Barasch A., and Peterson D.E. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39 (2003) 91-100
25. Chansky K., Benedetti J., and Macdonald J.S. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103 (2005) 1165-1171
26. Chen E. Impact of pre-existing psoriasis and Addison's disease on chemotherapy-induced mucositis in patients with hematological maliganancies. Pre-doctoral thesis, Harvard School of Dental Medicine; 2004.
27. Schwab M., Zanger U.M., Marx C., et al. Role of genetic and nongenetic factors for flurouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 26 (2008) 2131-2138
28. Bogunia-Kubik K., Polak M., and Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 617-622
29. Ambrosone C.B., Tian C., Ahn J., et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 8 (2006) R40
30. Ostman A., and Augstem M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19 (2009) 67-73
31. Pries R., and Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17 (2006) 141-146
32. Bose A., Chakraborty T., Chakraborty K., et al. Dysregulation in immune functions by peripheral blood mononuclear cells from head, neck squamous cell carcinoma patients. Cancer Immunol 8 (2008) 10
33. Body G.P., Rodriguize C.V., Chang N.Y., et al. Fever and infection in leukemic patients: a study of 464 consecutive patients. Cancer 41 (1978) 1610-1622
34. Donnelly J.P., Bellm L.A., Epstein J.B., et al. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 3 (2003) 405-412
35. Scarantino C. LeVeque, Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III, randomized study in head and neck cancer patients. J Support Oncol 4 (2006) 252-258
36. Lockhart P.B., Brennan M.T., Kent M.L., et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant 35 (2005) 713-720
37. El-Sayed S., Nabid A., Shelley W., et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20 (2002) 3956-3963
38. Rand K.H., Kramer B., and Johnson A.C. Cancer chemotherapy associated symptomatic stomatitis: role of Herpes simplex virus (HSV). Cancer 50 (1982) 1262-1265
39. Woo S.B., Sonis S.T., and Sonis A.L. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant patients. Cancer 66 (1990) 2375-2379
40. Djuric M., Jankovic L., Jankovic T., et al. Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J Oral Pathol Med 38 (2009) 167-173
41. Blijlevens N., and Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 18 (2007) 817-826
42. Tran CD, Sundar S, Howarth GS. Dietary zinc supplementation and methotrexate-induced small intestinal mucositis in metallothionein-knockout and wild-type mice. Cancer Biol Ther 2009;8, in press.
43. Bushel P.C., Forgery A., Grape F.B., et al. Granulocyte macrophage colony-stimulating factor: current practive and novel approaches. Clin J Oncol Nurs 6 (2002) 198-205
44. Aspinall R.J., and Pockros P.J. SCV-07. Curr Opin Invest Drugs 7 (2006) 180-185
45. Hunter A., Mahendra P., Wilson K., et al. Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant 43 (2009) 563-569
46. Porozov S., Cahalon L., Weiser M., et al. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol 11 (2004) 143-149